JP Morgan Chase’s BioRestorative Therapies BRTX Stock Holding History

JP Morgan Chase’s Portfolio BRTX Stock Details BRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$7	–	7537
2023 Q3	$7	Buy	+4	New	+$10	﹤0.01%	7328

Other funds holding BRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase's BRTX Position: Q4 2023 in Review

JP Morgan Chase sold out of BioRestorative Therapies (BRTX) in Q4 2023, closing a stake of 4 shares — an estimated $7 sold.

JP Morgan Chase first reported a position in BRTX in Q3 2023 and held it in 1 quarter. The position peaked at $7 in Q3 2023. 13 funds tracked by Wall St. Rank hold BRTX as of Q4 2023.

JP Morgan Chase reported no remaining BioRestorative Therapies position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 4 BioRestorative Therapies shares in Q4 2023, an estimated $7.
JP Morgan Chase first reported a position in BioRestorative Therapies in Q3 2023 and held it in 1 quarter.
JP Morgan Chase's BioRestorative Therapies position peaked at $7 in Q3 2023.
13 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.